Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 4
2001 pubmed

Interactions of growth hormone secretagogues and growth hormone-releasing hormone/somatostatin.

Tannenbaum. G S GS; Bowers. C Y CY

Key Findings

  • GHRP‑6 triggers GH release in a time‑dependent pattern that mirrors GHRH, indicating it follows the body’s natural GH pulse rhythm.
  • Neutralizing somatostatin does not boost GHRP‑6’s effect, showing GHRP‑6 does not act by suppressing somatostatin.
  • Blocking GHRH eliminates the GH response to GHRP‑6, proving that GHRP‑6’s action requires an intact GHRH pathway.

Practical Outcomes

  • For biohackers, schedule GHRP‑6 doses to coincide with natural GH peaks (e.g., before sleep) and consider combining it with a GHRH analog for stronger GH spikes. Do not rely on GHRP‑6 to overcome somatostatin‑related suppression; ensure your GHRH system is functional for optimal results.

Summary

The study shows that GHRP‑6 makes the pituitary release growth hormone by working through the body’s natural GHRH system, not by blocking somatostatin. Its effect depends on the timing of the body’s GH pulses, and if GHRH is blocked, GHRP‑6 stops working. This means GHRP‑6 works best when the GHRH pathway is active and may be more effective if paired with GHRH‑like compounds or timed to natural GH peaks.

Abstract

The class of novel synthetic compounds termed growth hormone secretagogues (GHSs) act in the hypothalamus through, as yet, unknown pathways. We performed physiologic and histochemical studies to further understand how the GHS system interacts with the well-established somatostatin (SRIF)/growth hormone-releasing hormone (GHRH) neuroendocrine system for regulating pulsatile GH secretion. Comparison of the GH-releasing activities of the hexapeptide growth hormone-releasing peptide-6 (GHRP-6) and GHRH administered intravenously to conscious adult male rats showed that the pattern of GH responsiveness to GHRP-6 was markedly time-dependent, similar to that observed with GHRH. Immunoneutralization of endogenous SRIF reversed the blunted GH response to GHRP-6 at trough times, suggesting that GHRP-6 neither disrupts nor inhibits the cyclical release of endogenous hypothalamic SRIF. By striking contrast, passive immunization with anti-GHRH serum virtually obliterated the GH responses to GHRP-6, irrespective of the time of administration. These findings suggest that the GHSs do not act by altering SRIF release but, rather, stimulate GH release via GHRH-dependent pathways. Our dual chromogenic and autoradiographic in situ hybridization experiments revealed that a subpopulation of GHRH mRNA-containing neurons in the arcuate (Arc) nucleus and ventromedial nucleus (VMN) of the hypothalamus expressed the GHS receptor (GHS-R) gene. These results provide strong anatomic evidence that GHSs may directly stimulate GHRH release into hypophyseal portal blood, and thereby influence GH secretion, through interaction with the GHS-R on GHRH- containing neurons. Altogether, these findings support the notion that an additional neuroendocrine pathway may exist to regulate pulsatile GH secretion, possibly through the influence of the newly discovered GHS natural peptide, ghrelin.

Study Information

Provider

pubmed

Year

2001

DOI

10.1385/endo:14:1:021